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Introduction
Glaucoma is a group of diseases that affect the optic 
nerve and lead to a progressive and irreversible loss of 
vision. Early stages of glaucoma can be asymptomatic, or 
individuals might notice missing or blurred areas in 
their field of vision.1 Late stages of the condition can lead 
to irreversible absolute blindness, particularly if left 
untreated. The main modifiable risk factor is elevated 
intraocular pressure (IOP); lifelong IOP control can halt 
disease progression.2,3
Globally, glaucomas are the most frequent cause of 
irreversible blindness.4 Africa has the highest prevalence 
of glaucoma of all world regions, which is estimated to be 
4·8%, as well as the highest incidence, with an expected 
increase from 10·31 million new cases in 2020 to 19·14 
million in 2040 due to increasing life expectancy and 
population growth.5 The prevalence of blindness due to 
glaucoma is higher in sub-Saharan Africa than in any 
other world region.4 This situation is met by limited 
resources in many regions of sub-Saharan Africa; the 
mean number of ophthalmologists is 3·7 per million 
people in low-income countries versus 76·2 per million 
people in high-income countries.6
Reducing IOP by medical therapy with eye drops, 
surgery, or laser treatment is currently the only available 
treatment approach for delaying glaucoma progression. 
In sub-Saharan Africa, most people are either treated 
with the low-cost eye drops, timolol, or with surgery.7,8 
However, regular application of drops is often hampered 
by non-adherence, scarce availability, long-term costs, 
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Summary
Background Glaucoma is a major cause of sight loss worldwide, with the highest regional prevalence and incidence 
reported in Africa. The most common low-cost treatment used to control glaucoma is long-term timolol eye drops. 
However, low adherence is a major challenge. We aimed to investigate whether selective laser trabeculoplasty (SLT) 
was superior to timolol eye drops for controlling intraocular pressure (IOP) in patients with open-angle glaucoma.
Methods We did a two-arm, parallel-group, single-masked randomised controlled trial at the Eye Department of 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania. Eligible participants (aged ≥18 years) had open-angle glaucoma 
and an IOP above 21 mm Hg, and did not have asthma or a history of glaucoma surgery or laser. Participants were 
randomly assigned (1:1) to receive 0·5% timolol eye drops to administer twice daily or to receive SLT. The primary 
outcome was the proportion of eyes from both groups with treatment success, defined as an IOP below or equal to target 
pressure according to glaucoma severity, at 12 months following randomisation. Re-explanation of eye drop application 
or a repeat SLT was permitted once. The primary analysis was by modified intention-to-treat, excluding participants lost 
to follow-up, using logistic regression; generalised estimating equations were used to adjust for the correlation between 
eyes. This trial was registered with the Pan African Clinical Trials Registry, number PACTR201508001235339.
Findings 840 patients were screened for eligibility, of whom 201 (24%) participants (382 eligible eyes) were enrolled 
between Aug 31, 2015, and May 12, 2017. 100 (50%) participants (191 eyes) were randomly assigned to the timolol 
group and 101 (50%; 191 eyes) to the SLT group. After 1 year, 339 (89%) of 382 eyes were analysed. Treatment was 
successful in 55 (31%) of 176 eyes in the timolol group (16 [29%] of 55 eyes required repeat administration counselling) 
and in 99 (61%) of 163 eyes in the SLT group (33 [33%] of 99 eyes required repeat SLT; odds ratio 3·37 [95% CI 
1·96–5·80]; p<0·0001). Adverse events (mostly unrelated to ocular events) occurred in ten (10%) participants in the 
timolol group and in eight (8%) participants in the SLT group (p=0·61).
Interpretation SLT was superior to timolol eye drops for managing patients with open-angle high-pressure glaucoma 
for 1 year in Tanzania. SLT has the potential to transform the management of glaucoma in sub-Saharan Africa, even 
where the prevalence of advanced glaucoma is high.
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and side-effects. Trabeculectomy, the main surgical 
procedure for treating glaucoma, can effectively reduce 
IOP; however, the operation has a long learning curve, is 
offered in relatively few eye units across sub-Saharan 
Africa, can have clinically significant complications, and 
has a low uptake in some populations.8–12 Selective laser 
trabeculoplasty (SLT) is a rapid outpatient procedure 
used to reduce IOP. SLT increases aqueous fluid outflow 
from the eye, which drains through the trabecular 
meshwork. There is increasing evidence supporting its 
use as a primary intervention.13,14 Lasers, especially SLT, 
could be part of future treatment for glaucoma in sub-
Saharan Africa.15 However, to date, there have been no 
published trials of SLT in sub-Saharan Africa, and no 
trials worldwide have compared SLT with timolol as the 
standard treatment option.
We aimed to investigate whether SLT was superior to 
timolol eye drops for controlling IOP in patients with 
open-angle glaucoma in a Tanzanian setting.
Methods
Study design
We did a two-arm, parallel-group, single-masked 
randomised controlled trial at the Eye Department of 
Kilimanjaro Christian Medical Centre (KCMC), Moshi, 
northern Tanzania.
The trial was approved by the research ethics review 
committees of the National Institute for Medical 
Research in Dar es Salaam, Tanzania (NIMR/HQ/R.8a/
Vol IX/1929), the Kilimanjaro Christian Medical 
University College in Moshi, Tanzania (number 800), 
and the London School of Hygiene & Tropical Medicine 
in London, UK (LSHTM Ethics Ref 7166). The trial was 
done in compliance with the Declaration of Helsinki and 
the International Conference on Harmonisation–Good 
Clinical Practice. An independent data and safety 
monitoring board was appointed by the trial steering 
committee. A patient steering group provided input on 
different aspects of the trial such as study design and 
questionnaires.
Participants
Patients who attended the ophthalmology clinic at KCMC 
were screened for eligibility. The main inclusion criterion 
was diagnosis of chronic high-pressure open-angle 
glaucoma, defined as an IOP of more than 21 mm Hg 
and a combination of structural and functional changes 
(category 1 of the International Society of Geographic and 
Research in context
Evidence before this study
Preventing irreversible blindness from glaucoma can be achieved 
by reducing intraocular pressure (IOP) with daily eye drops, eye 
surgery, and laser treatment. African populations have the 
highest prevalence and incidence of open-angle glaucoma and 
the highest prevalence of blindness due to glaucoma worldwide. 
The Lancet Global Health Commission on global eye health called 
for research into cost-effective glaucoma interventions, 
especially those that are applicable in low-income and middle-
income countries. Timolol eye drops are the most affordable and 
most commonly available treatment among drugs to reduce IOP. 
However, erratic application, systemic and local side-effects, and 
high long-term costs led to a search for alternatives methods to 
reduce IOP, such as selective laser trabeculoplasty (SLT). We did 
several literature searches using MEDLINE (via PubMed), ISRCTN, 
and PACTR trial registries, without any language or date 
restrictions, between Oct 3, 2012, and March 16, 2015, for 
published or ongoing trials of SLT as an alternative to timolol. 
Applying the terms “selective laser trabeculoplasty” (or “SLT”) 
and “timolol” showed no results. A wider search using “selective 
laser trabeculoplasty” (or “SLT”) without “timolol” found five 
randomised controlled trials that compared SLT with more 
expensive eye drops in different settings and reported SLT to be a 
feasible and safe alternative to medical ocular treatment.
Added value of this study
This trial was done in Tanzania and enrolled 201 patients with 
predominantly advanced glaucoma, reflecting the typical 
spectrum and associated challenges of glaucoma care in this 
region. By contrast, most patients in the previous trials involving 
SLT and more expensive eye drops had early or moderate 
glaucoma. Both eyes were enrolled if eligible and analysed using 
statistical methods that considered the correlation between the 
two eyes of a participant. This methodology efficiently used all 
available data, saving time and resources, and making optimal 
use of participants’ engagement. 12 months after 
randomisation, the estimated odds for success using SLT were 
3·37 times higher than those for success using 0·5% timolol eye 
drops. The odds ratio was not modified by other factors. Mean 
IOP reduction was 1·5 mm Hg (SD 7·5) in the timolol group and 
6·3 mm Hg (6·4) in the SLT group between the baseline visit and 
visits at failure, success at 1 year, or before loss to follow-up. 
Safety, acceptance, vision-related quality of life, and preservation 
of visual acuity were similar in both groups after 1 year. Eye care 
units in the region would need to treat around 500 eyes per year 
with SLT to cover the cost of the procedure, which would cost an 
amount similar to a 1-year supply of timolol eye drops.
Implications of all the available evidence
This trial adds to the existing evidence that SLT is an important 
addition to the treatment options for glaucoma, and extends 
this evidence to regions where advanced glaucoma is more 
common and treatment resources and options are limited. 
The prevalence of glaucoma is expected to increase in the 
coming decades due to increasing life expectancy and population 
growth, especially in low-income and middle-income regions. 
Therefore, SLT could help to prevent vision loss and blindness 
from glaucoma in regions where its prevalence is highest.
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Epidemiologic Ophthalmology).16 Structural changes 
were specified as thinning of the optic nerve head rim 
(stage 5 or above on the Disc Damage Likelihood Scale, a 
cup-to-disc ratio of ≥0·7, or a cup-to-disc ratio asymmetry 
between two eyes of ≥0·2).17 Functional changes included 
a glaucomatous visual field defect or relative afferent 
pupil defect. Inclusion criteria also permitted high-
risk glaucoma suspect (IOP >25 mm Hg, structural 
changes as above, no visual field defect) or high-risk 
ocular hyperten sion (IOP >32 mm Hg, no structural 
or functional defect), and International Society of 
Geographic and Epidemiologic Ophthalmology category 
2 (cup-to-disc ratio of ≥0·8 or cup-to-disc ratio asymmetry 
of ≥0·3 if a visual field could not be satisfactorily 
completed).16 Exclusion criteria included being aged 
younger than 18 years or having an opaque cornea, 
narrow angle (<2 on the Shaffer scale in two quadrants), 
absolute blindness (no perception of light), history of 
previous uveitis, any previous glaucoma surgery or 
laser treatment, neovascular or traumatic glaucoma, 
and history of asthma or bradycardia, which can be 
exacerbated by timolol eye drops. The full exclusion 
criteria are listed in appendix 4 (p 2). Patients who 
reported using eye drops before the trial had a 4-week 
washout period. Eligible patients were informed about 
the study in detail in Kiswahili and, if interested, invited 
to return on a different day for the baseline examination. 
During this assessment, written informed consent was 
obtained in Kiswahili before participants were enrolled.
Randomisation and masking
The randomisation sequence was generated by an 
independent statistician with a variable block size 
between 4 and 8. Sequentially numbered and sealed 
opaque envelopes contained the allocation of participants 
to either the SLT or the timolol group (1:1). One or both 
eyes were enrolled, depending on eligibility, and were 
treated identically. Participants were enrolled and 
assigned to an intervention arm together by at least two of 
the following individuals: HP, EdM, SM, KMK, and EiM. 
Due to the nature of the interventions, participants, 
principal investigators, and health-care staff administering 
treatments could not be masked to treatment allocation; 
however, the clinicians who examined IOP were masked 
to the trial arm, the individual IOP threshold, and 
previous IOP measurements of the participant, and were 
not involved in any other aspect of the trial.
Procedures
During the baseline assessment, a detailed clinical history 
was taken. We assessed vision-related quality of life using 
the 20-item cross-cultural WHO visual functioning 
questionnaire (WHO/PBD-VF20).18 Additional question-
naires included the Patient Outcome and Experience 
Measure and the Glaucoma Symptom Scale.19,20
Visual acuity was measured at 2 m in a dimmed room 
(Peek Acuity app [version 3.5.0]). Static visual field 
perimetry was done with the Swedish interactive 
threshold algorithm standard 24-2 or 10-2 programme 
(II-i series system software version 4.2) of the Humphrey 
HFA II 740i Visual Field Analyzer (Carl Zeiss Meditec 
AG, Jena, Germany).21 The Disc Damage Likelihood 
Scale was used to stratify glaucoma severity into 
moderate (stage 5–7) and advanced (stage 8–10). 
Glaucoma-related structural features were assessed by 
slit-lamp examination of the anterior eye segment, 
pachymetry (central corneal thickness), gonioscopy, 
fundus imaging, and indirect fundoscopy of the optic 
nerve head.
Standardised examiners measured baseline IOP before 
treatment allocation, following a standard operating 
procedure. This procedure included measuring IOP with 
a calibrated Goldmann Applanation Tonometer (Haag 
Streit, Koeniz, Switzerland) twice within 5 mins. If the 
difference between the first two measurements was up to 
2 mm Hg, the mean IOP was noted. Otherwise, a third 
measurement was obtained and the median was 
recorded.22 The repeatability coefficient of Goldmann 
tonometry is around 2·5 mm Hg.23
Several focus group discussions involving patients, 
relatives, and eye care specialists were held on the two 
treatment options and other contextual factors for 
glaucoma during the trial. The results from the 
questionnaires, focus group discussions, and other 
glaucoma-related functional or structural changes will be 
reported elsewhere.
Following the baseline assessment and enrolment, 
patients randomly assigned to the SLT laser intervention 
(SLT group) received amethocaine (topical anaesthesia), 
0·2% topical brimonidine (IOP spike prevention), and 
1·0% topical prednisolone (inflam matory response 
control) 15 mins before the procedure. The chamber 
angle was then visualised with the Latina goniolens 
supplied with the SLT laser (Lumenis Selecta II 
Lumenis, Yokneam, Israel). Approximately 100 laser 
spots were applied to cover 360° of the trabecular 
meshwork. Starting energy level was 0·6 mJ, which was 
continuously titrated in steps of 0·1 mJ until cavitation 
bubbles appeared in around a third of laser spot 
applications. The eye, including IOP, was examined 
about 1 h after SLT. All SLT procedures were done on the 
day of treatment allocation by one ophthalmologist (HP), 
who was trained in the procedure at University Hospitals 
Birmingham (Birmingham, UK) by PS and had com-
pleted around 100 SLT procedures before the trial.
Participants randomly assigned to the standard 
treatment arm (timolol group) received 0·5% timolol eye 
drops to administer twice daily. The importance, side-
effects, and application of eye drops were explained by a 
study assistant to participants and accompanying helpers 
in Kiswahili using a standard protocol (appendix 4 
pp 12–13). Adherence was estimated by asking partici-
pants at each follow-up visit how frequently they had 
missed their eye drops. Both treatment options were 
See Online for appendix 4
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provided free of charge to the patient, and transport cost 
was subsidised to further increase adherence.8,24
Follow-up assessments were scheduled at 2, 6, 9, and 
12 months. Masked examiners measured IOP on each 
follow-up visit following the same procedure as was used 
during baseline assessment. Additional safety visits were 
arranged if the supervising clinician considered this to 
be necessary. One IOP measurement of up to 2 mm Hg 
above target IOP was allowed on one of the follow-up 
visits without triggering a repeat intervention or being 
considered a treatment failure. If the IOP was more than 
2 mm Hg above target or up to 2 mm Hg above target for 
the second time, repeat SLT or counselling was provided. 
If the IOP exceeded the target on any subsequent 
occasion again, the eye was considered to have a 
treatment failure and exited from the trial, and the 
patient received additional treatment (including the 
intervention from the other intervention arm, additional 
eye drops, or trabeculectomy; appendix 4 p 4). 
Furthermore, if the IOP was more than 40 mm Hg at any 
visit, the eye was considered to have a treatment failure 
and was exited from the trial immediately; additional 
treatment was provided to the participant’s eye.
To estimate the cost of an SLT laser procedure, we 
followed a bottom-up micro-costing approach assuming 
that the equipment had a lifetime of 10 years and that 
the SLT treatment was done on demand during a 
glaucoma clinic by an ophthalmologist earning a 
standard salary.13,25 Variable and fixed costs were 
calculated and a threshold analysis was done estimating 
total costs for eight production scenarios, depending on 
the annual number of treatments (appendix 4 pp 10–12). 
The annual cost of timolol eye drops was identified 
using the median of three prices at pharmacies across 
Tanzania and was used as a reference to determine the 
number of SLT procedures that would result in 
comparable cost. Both annual treatment costs were then 
compared with an affordability threshold of 2·5% of 
Tanzania’s gross domestic product per capita, as a proxy 
of income.26
Outcomes
The primary outcome was the proportion of eyes 
from both intervention groups with treatment success at 
12 months following randomisation. For patients with 
advanced glaucoma (stage 8–10 according to the Disc 
Damage Likelihood Scale), this target IOP was 
18 mm Hg or below and for those with moderate 
glaucoma (stage 5–7), this target was 21 mm Hg or below. 
Secondary outcomes were safety, acceptance, vision-
related quality of life, adherence, preservation of visual 
acuity and visual fields, other glaucoma-related functional 
or structural changes, other IOP-related outcomes, 
analyses of focus group discussions, cost, and treatment 
affordability.
Statistical analysis
The trial was powered to test the hypothesis that SLT is 
superior to timolol eye drops. From the literature and 
retrospective data from the Eye Department at KCMC, 
we anticipated that the proportions of success after 
12 months would be 60% for timolol and 75% for SLT.27 
Allowing for a loss to follow-up of 20%, a sample size of 
360 eyes was estimated to provide 80% power with 
95% confidence to detect such a difference.
The primary outcome was a binary variable defined as 
treatment success at 12 months, compared between the 
two treatment arms. Analysis of the primary outcome 
was by modified intention-to-treat using a logistic 
regression model, in which participants lost to follow-up 
were excluded, with generalised estimating equations 
(GEE) to account for the absence of inde pendence 
between eyes, if both eyes were included. The primary 
analysis was unadjusted, although baseline characteristics 
were examined for balance between arms.
Secondary outcomes were described and compared 
between the two treatment arms. A change in visual acuity 
of two or more lines on the logarithm of the minimum 
angle of resolution (logMAR) chart (equals ≥0·2 logMAR 
between baseline and the last visit, either in the event of a 
failure, before loss to follow-up, or success at 12 months) 
was defined as a loss of central vision and compared using 
logistic regression with GEE by arm.28 Acceptance was 
described as the number of times a participant refused 
an intervention at any of the follow-up visits after 
being randomly assigned. WHO/PBD-VF20 items were 
Figure 1: Trial profile
SLT=selective laser trabeculoplasty. The full list of reasons for exclusion are provided in appendix 4 (p 3).
840 patients assessed for eligibility 
201 patients (382 eyes) randomly assigned
100 patients (191 eyes) allocated to 
timolol eye drops
91 patients (176 eyes) included in the primary 
outcome analysis at 12 months
9 patients (15 eyes) discontinued 
1 patient (2 eyes) too ill to return
1 patient (2 eyes) not contactable
3 patients (5 eyes) moved away
3 patients (5 eyes) declined
1 patient (1 eye) died
101 patients (191 eyes) allocated to SLT
86 patients (163 eyes) included in the primary 
outcome analysis at 12 months
15 patients (28 eyes) discontinued 
1 patient (1 eye) too ill to return
1 patient (2 eyes) not contactable
3 patients (6 eyes) moved away
7 patients (14 eyes) declined
3 patients (5 eyes) died
639 patients excluded 
101 had no perception of light
160 had previous glaucoma surgery or laser
336 met other exclusion criteria
13 declined 
29 for other reasons
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divided into the general functioning, visual symptoms, 
and psychosocial subscales, and summary scores were 
transformed to a scale (0–100), with 100 as the highest 
possible vision-related quality of life score.18 Affordability 
was described as whether a person had sufficient income 
to pay for health-care services, treatment, or costs 
(appendix 4 p 12).29
We tested for evidence of effect modification by the 
stage of glaucoma and baseline IOP. A sensitivity analysis 
was done to provide the most conservative estimate, 
considering all participants lost to follow-up as failure in 
the more successful arm and as success in the less 
successful arm. Patients lost to follow-up were compared 
with those who completed the trial with respect to age, 
sex, stage of glaucoma, intervention, visual field defect, 
visual acuity, and travel details using logistic regression 
with GEE. Differences between arms in time to an event 
were assessed by plotting survival curves and a Cox 
regression analysis, by use of a shared frailty model to 
account for dependency between the two eyes. Other 
potential determinants of success were investigated 
using logistic regression with GEE. To prevent 
multicollinearity in a fully adjusted model, all potential 
determinants were first screened for inclusion using a 
univariable model and GEE. Any factor in which p<0·2 
was included in the fully adjusted model. Backward 
stepwise selection was then employed to find the most 
parsimonious logistic regression model, with p<0·05 for 
all predictors.
Data were managed in a custom built database in 
Microsoft Access 2016. Stata (version 16.1) was used to 
compute the statistical analysis. A data safety monitoring 
board oversaw the study. This trial was registered 
with the Pan African Clinical Trials Registry, number 
PACTR201508001235339.
Timolol group SLT group 
Participant characteristics
Number of participants 100 101
Age, years 65·09 (10·79) 67·40 (12·33)
Sex
Female 46 (46%) 37 (37%)
Male 54 (54%) 64 (63%)
Ethnic group
Chagga 54 (54%) 57 (56%)
Pare 18 (18%) 23 (23%)
Meru 4 (4%) 4 (4%)
Maasai 4 (4%) 1 (1%)
Sambaa 3 (3%) 2 (2%)
Other 17 (17%) 14 (14%)
Education
Less than secondary level 70 (70%) 63 (62%)
Secondary level or higher 30 (30%) 38 (38%)
Family history of glaucoma*
No 76 (76%) 77 (76%)
Yes 24 (24%) 24 (24%)
Travel distance, km
<50 51 (51%) 54 (53%)
≥50 49 (49%) 47 (47%)
Ocular characteristics
Number of eyes 191 191
Visual acuity (logMAR) 0·48 (0·69) 0·49 (0·66)
Visual acuity (WHO categories)
Normal vision 147 (77%) 145 (76%)
Low vision 20 (10%) 23 (12%)
Blind 24 (13%) 23 (12%)
Exfoliation glaucoma
No 167 (87%) 166 (87%)
Yes 24 (13%) 25 (13%)
Pseudophakia
No 185 (97%) 177 (93%)
Yes 6 (3%) 14 (7%)
(Table 1 continues in next column)
Timolol group SLT group 
(Continued from previous column)
Vertical cup-to-disc-ratio 0·85 (0·15) 0·84 (0·16)
Intraocular pressure, mm Hg 26·96 (7·52) 26·38 (6·28)
Optic nerve head damage (DDLS)
5 34 (18%) 42 (22%)
6 20 (10%) 22 (12%)
7 25 (13%) 19 (10%)
8 47 (25%) 40 (21%)
9 33 (17%) 33 (17%)
10 32 (17%) 35 (18%)
Stage of glaucoma (DDLS)
Moderate (stage 5–7) 79 (41%) 83 (43%)
Advanced (stage 8–10) 112 (59%) 108 (57%)
Visual field (24-2), mean defect, 
dB†
–18·29 (11·09) –16·02 (10·94)
Visual field (10-2), mean defect, 
dB†
–33·92 (0·58) –30·71 (4·40)
Central corneal thickness, µm‡ 522·89 (34·79) 519·16 (34·51)
Previous timolol eye drops§
No 83 (43%) 93 (49%)
Yes 108 (57%) 98 (51%)
Data are mean (SD) or n (%), unless otherwise indicated. SLT=selective laser 
trabeculoplasty. logMAR=logarithm of the minimum angle of resolution. 
DDLS=Disc Damage Likelihood Scale. *In a first-degree relative. †Visual field 
examinations: 347 eyes completed 24-2 (175 in timolol group vs 172 in SLT 
group); eight eyes completed 10-2 only (four in timolol group vs four in SLT 
group); no visual field possible in 27 eyes (12 in timolol group vs 15 in SLT group) 
due to reduced central vision. ‡Central corneal thickness measurements missing 
in 13 eyes (five in timolol group vs eight in SLT group) due to temporary failure of 
the pachymeter. §Based on patient history. 
Table 1: Baseline participant and ocular characteristics
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Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report.
Results
840 patients with glaucoma who attended the Eye 
Department at KCMC were screened for eligibility 
(figure 1; appendix 4 p 3). Of those screened, 201 (24%) 
eligible partici pants (382 eyes) were enrolled between 
Aug 31, 2015, and May 12, 2017, of whom 100 (50%) of 
participants (191 eyes) were randomly assigned to the 
timolol group and 101 (50%; 191 eyes) to the SLT group. 
All participants were members of one of the ethnic 
groups living in Tanzania (table 1). At 12 months, 
177 (88%) patients (339 eyes) were included in the 
analysis; 24 (12%) patients (43 eyes) had been lost to 
follow-up. The mean age of 201 people enrolled in the 
trial was 66·3 years (SD 11·6) and 83 participants were 
female. The mean age of 639 patients not enrolled was 
65·0 years (15·5) and 268 participants were female.
Loss to follow-up was not associated with age, sex, 
stage of glaucoma, intervention arm, or level of visual 
acuity. There was evidence that patients with advanced 
visual field defects were less likely (p=0·0018) and 
patients who needed a guide for their journey to the eye 
hospital were more likely (p=0·016) to be lost to follow-
up. However, these inferences are based on few patients 
who were lost to follow-up (24 patients [12%]; figure 1).
A successful IOP reduction 1 year after the start of 
treatment was reported in 55 (31%) of 176 eyes in the 
timolol group (16 [29%] of 55 eyes required repeat 
counselling) and in 99 (61%) of 163 eyes in the SLT group 
(33 [33%] of 99 eyes required a repeat SLT). The 
unadjusted logistic regression model (ie, GEE) for the 
relationship between intervention and success estimated 
an odds ratio (OR) of SLT over timolol eye drops of 3·37 
(95% CI 1·96–5·80; p<0·0001; table 2). Cox regression 
analysis showed a hazard ratio of 0·16 (0·09–0·30; 
p<0·0001; figure 2). Detailed IOP results can be found in 
the appendix 4 (pp 5–6).
A reduction of central vision occurred in 36 (19%) of 
187 eyes in the timolol group and in 40 (21%) of 188 in the 
SLT group. There was no evidence of a difference 
between interventions (OR 1·16 [95% CI 0·66–2·06]; 
p=0·60). Vision-related quality of life measured with the 
WHO/PBD-VF20 showed no differences between the 
two groups (table 3).
Self-reported adherence to eye drop use in the timolol 
group was high (table 4). 56–75% of patients reported 
daily application of eye drops during the 2 weeks before 
the follow-up visit, 15–24% of patients reported missing 
eye drops for 1–2 days, and only 4–20% of patients 
reported missing eye drops for more than 2 days. No 
participant refused either timolol eye drops or SLT within 
the first year, including repeat interventions.
From an eye care provider’s perspective, the variable 
cost per SLT treatment was estimated to be US$2·57. 
Annual fixed costs were $4960, including the depreciation 
of the initial purchase over the 10 years, the annual 
inspection, and an assumption of two repairs.13 Travel 
expenses of technicians were added, which might be 
substantial where services are not available in a country 
(appendix 4 pp 10–12). The SLT laser has been in 
operation at KCMC since 2015 without needing repair. 
With a scenario of 500 eyes treated per year, the total 
Success Univariable OR 
(95% CI)




Timolol 55/176 (31%) 1 (ref) ·· ·· ··
SLT 99/163 (61%) 3·37 (1·96–5·80) <0·0001 5·35 (2·77–10·31) <0·0001
Sex
Female 66/142 (46%) 1 (ref) ·· ·· ··
Male 88/197 (45%) 0·92 (0·54–1·57) 0·77 ·· ··
Age groups, years
<70 101/211 (48%) 1 (ref) ·· ·· ··
≥70 53/128 (41%) 0·74 (0·43–1·28) 0·28 ·· ··
Education
Less than secondary 
level
92/225 (41%) 1 (ref) ·· ·· ··
Secondary level or 
above
62/114 (54%) 1·68 (0·97–2·93) 0·066 ·· ··
Travel distance to KCMC, km
<50 87/185 (47%) 1 (ref) ·· ·· ··
≥50 67/154 (44%) 0·86 (0·51–1·46) 0·58 ·· ··
History of timolol eye drops
No 75/151 (50%) 1 (ref) ·· ·· ··
Yes 79/188 (42%) 0·73 (0·44–1·22) 0·24 ·· ··
Pseudophakia
Phakic 145/324 (45%) 1 (ref) ·· ·· ··
Pseudophakic 9/15 (60%) 1·16 (0·41–3·29) 0·78 ·· ··
Exfoliation glaucoma
No 147/297 (49%) 1 (ref) ·· ·· ··
Yes 7/42 (17%) 0·16 (0·06–0·44) 0·0004 0·16 (0·05–0·46) 0·0009
Central corneal thickness, µm*
<520 67/164 (41%) 1 (ref) ·· ·· ··
≥520 85/172 (49%) 1·43 (0·88–2·33) 0·15 ·· ··
Angle pigmentation
Light pigmentation 132/289 (46%) 1 (ref) ·· ·· ··
Strong pigmentation 22/50 (44%) 1·06 (0·53–2·14) 0·87 ·· ··
Stage of glaucoma (DDLS)
Moderate (stage 5–7) 108/145 (74%) 1 (ref) ·· ··
Advanced (stage 8–10) 46/194 (24%) 0·14 (0·09–0·23) <0·0001 0·11 (0·06–0·20) <0·0001
Intraocular pressure, mm Hg
<25 100/153 (65%) 1 (ref) ·· ··
≥25 54/186 (29%) 0·27 (0·17–0·44) <0·0001 0·33 (0·19–0·60) 0·0003
Visual acuity (WHO categories)
Normal vision 135/263 (51%) 1 (ref) ·· ·· ··
Low vision 12/33 (36%) 0·64 (0·33–1·25) ·· ·· ··
Blind 7/43 (16%) 0·38 (0·21–0·71) 0·0060† ·· ··
(Table 2 continues on next page)
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costs for one procedure are approximately $12·49. Since 
both eyes are often treated, this figure corresponds to 
250–400 patients treated per year to cover the costs and 
offer the laser treatment at a price of $12·49 per treatment 
using a not-for-profit eye care service model (appendix 4 
p 11). To achieve successful treatment with SLT in this 
study, 33 eyes required two procedures and 66 eyes were 
treated after one treatment. Thus, from the patient’s 
perspective, an average of 1·33 treatments would be 
required, increasing the average cost to approximately 
$16·61 per eye for a successful outcome, excluding 
travelling expenses. Annual therapy with timolol eye 
drops cost around $16·32 per eye in Tanzania. Therefore, 
with around 500 treatments per year, the SLT treatment 
can be offered, covering costs, at a similar price as timolol 
eye drops. The annual GDP per capita in Tanzania 
in 2019 was reported to be $1122·12, so any annual 
treatment cost below $28·05 can be considered 
affordable. Thus, the annual treatment cost of timolol 
and SLT for one eye are below this threshold (assuming 
500 procedures per year in an eye health unit). For SLT, 
the treatment costs for two eyes can also be considered 
affordable for most patients as 66 (67%) of 99 eyes only 
required one treatment for a successful outcome (annual 
treatment cost for two eyes of $24·98).
We used a sensitivity analysis to assess whether the 
primary outcome results were possibly influenced by 
loss to follow-up. The hypothetical scenario considered 
all patients who were lost to follow-up in the SLT group 
to be failures and those in the timolol group to be 
successes, assuming the worst possible scenario for the 
SLT group. The OR of success of SLT was 1·88 (95% CI 
1·13–3·11; p=0·015).
There was no evidence of an effect modification in the 
OR of SLT over timolol by the stage of glaucoma (p=0·55) 
or by the baseline IOP (p=0·14; appendix 4 p 8).
Other potential determinants for success were 
evaluated (table 2). The most parsimonious multivariable 
model showed an association between success and SLT 
(vs timolol) as the randomisation arm (OR 5·35 [95% CI 
2·77–10·31]; p<0·0001), high (vs low) IOP at baseline 
(0·33 [0·19–0·60]; p=0·0003), advanced (vs moderate) 
stage of glaucoma (0·11 [0·06–0·20]; p<0·0001), and the 
presence (vs absence) of exfoliation material (0·16 
[0·05–0·46]; p=0·0009).
In total, there were ten (10%) ocular and systemic 
adverse events in the timolol group and eight (8%) in the 
SLT group (OR 0·77 [95% CI 0·29–2·05]; p=0·61; 
table 5). Four patients died during the 1-year follow-up 
period (one in the timolol group vs three in the SLT 
group) from known pre-existing general medical 
conditions. SLT was associated with several transient 
(<1 h) side-effects (appendix 4 p 9). The baseline SLT 
procedure caused no pain during 69 (36%) of 191 
baseline laser procedures, mild pain during 103 (54%), 
moderate pain during 15 (8%), and severe pain during 
one (<1%). No baseline SLT procedure triggered an IOP 
Figure 2: Kaplan-Meier curve of time to treatment failure
Differences between the two intervention groups in time to an event was 
assessed with a Cox regression analysis using a shared frailty model to account 

































































Baseline visit 79·5 (17·7) 72·5 (21·2) 1·91 (–6·17 to 10·00) ··
12-month visit/Δ (SD) 88·2 (15·6)/8·6 (19·7) 83·1 (15·8)/10·5 (15·6) ·· 0·64
Visual symptoms
Baseline visit 66·4 (17·3) 68·3 (21·9) –2·67 (–11·89 to 6·55) ··
12-month visit/Δ (SD) 74·7 (16·9)/8·3 (23·8) 74·0 (16·9)/5·7 (16·9) ·· 0·57
Psychosocial
Baseline visit* 77·2 (17·3) 74·4 (21·1) –5·29 (–15·02 to 4·44) ··
12-month visit/Δ (SD) 87·5 (17·3)/10·3 (15·2) 79·3 (24·2)/5·0 (23·1) ·· 0·28
Data are mean (SD), unless otherwise indicated. Mean (SD) of total scores (0–100) of three subscales of WHO/PBD-VF20 
questionnaires for patients with success at 12 months (if both eyes were enrolled, the status of the right eye was 
considered), so 28 patients in the timolol group and 50 patients in the SLT group. Higher scores represent a better 
vision-related quality of life. Estimated group difference (Δ), 95% CI, and p values from linear regression of differences 
between interventions.  SLT=selective laser trabeculoplasty. Δ=delta or difference. *Data of one patient missing in the 
SLT group.
Table 3: Vision-related quality of life
Success Univariable OR 
(95% CI)
p value Multivariable OR 
(95% CI)
p value
(Continued from previous page)
Glaucoma categories
Early 63/81 (78%) 1 (ref) ·· ·· ··
Moderate 31/46 (67%) 0·46 (0·23–0·94) ·· ·· ··
Advanced 15/35 (43%) 0·33 (0·15–0·73) ·· ·· ··
Severe 40/150 (27%) 0·13 (0·07–0·23) ·· ·· ··
End stage 5/27 (19%) 0·10 (0·04–0·27) <0·0001† ·· ··
Data are n/N (%). Results of 339 eyes analysed at 12 months using univariable and multivariable analyses of potential 
factors associated with success using logistic regression with general estimating equations. Parameters with p<0·2 in 
the log likelihood ratio test were included in the initial multivariable model. Backward stepwise selection was then 
employed to find the most parsimonious logistic regression model, in which all predictors had p<0·05. This final model 
included intervention, intraocular pressure at baseline, stage of glaucoma, and exfoliation glaucoma. OR=odds ratio. 
SLT=selective laser trabeculoplasty. KCMC=Kilimanjaro Christian Medical Centre. DDLS=Disc Damage Likelihood Scale. 
*Central corneal thickness missing for three eyes. †Wald test for trend. 
Table 2: Predicted ORs for success
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spike of more than 5 mm Hg within the first hour, and 
two (2%) of 104 repeat SLT procedures were followed by 
reversible IOP spikes.
Discussion
This randomised controlled trial compared timolol eye 
drops with SLT in patients with glaucoma in Tanzania. 
SLT was superior to timolol in controlling IOP, with 
an OR of 3·37 in favour of SLT (95% CI 1·96–5·80; 
p<0·0001). This difference between the two interventions 
was not significantly modified by the stage of glaucoma 
or baseline IOP.
A previous meta-analysis estimated the mean differ-
ence in IOP reduction between timolol and placebo at 
3 months as 3·70 mm Hg (95% CI 3·16–4·24).30 We 
observed a comparable IOP reduction in the timolol 
group of 3·22 mm Hg (SD 7·51) at the 2-month visit. 
IOP lowering in the SLT group at the 2-month visit was 
6·28 mm Hg (SD 6·13). To our knowledge, no previous 
direct comparison has been made between SLT and 
timolol eye drops, the most affordable and commonly 
available IOP lowering drug.26,30
Gazzard and colleagues13 compared SLT with any 
conservative treatment to reduce IOP in a predominantly 
White study population in the UK. The authors followed 
an algorithm to define individual target IOPs and 
progression rules. Of the 536 eyes treated with SLT 
first, 419 (78%) required no additional medication 
to reach target IOP, and 321 (60%) required only a 
single SLT treatment.13 Realini and colleagues31 reported a 
study of 72 participants from an African Caribbean 
population with a 12-month success rate of 78%, using a 
20% reduction from baseline IOP as success criterion.
Our adjusted multivariable model showed that a more 
advanced stage of glaucoma, higher baseline IOP, and 
the presence of exfoliation glaucoma were all associated 
with a decreased probability of success. In our study 
protocol, the stage of glaucoma determined the target 
IOP, which needs to be lower in advanced glaucoma.2 A 
greater reduction in IOP is more difficult to achieve in 
general; therefore, the probability of success is likely 
to be lower in eyes with advanced glaucoma and a 
higher baseline IOP (appendix 4 p 7) than in those 
with moderate glaucoma and a lower baseline IOP. 
Exfoliation glaucoma reduced the probability of success 
in both intervention groups. To date, few clinical trials 
with small sample sizes have shown inconclusive results 
concerning the role of exfoliation glaucoma.32 Our results 
suggest that, although the subtype of exfoliation 
glaucoma is challenging to treat overall, SLT might still 
be a better option than timolol (appendix 4 p 7). Some 
regions in sub-Saharan Africa are affected by a 
particularly high prevalence of exfoliation glaucoma.33
Only mild adverse effects and no serious treatment-
related adverse events were reported in either group, 
similarly to other studies.13 SLT caused reversible changes 
in the anterior chamber and corneal endothelium, 
as well as no or mild pain in most patients.34 After 
excluding patients with asthma and bradycardia, timolol 
eye drops caused no clinically significant com plaints. 
The extensive counselling by two Tanzanian research 
assistants probably played an important role in the high 
acceptance of both treatment methods, which could have 
possibly been lower otherwise. This trusting relationship 
and the provision of treatment at no cost probably 
contributed to the higher adherence to timolol eye drops 
in this trial compared with that observed in other 
studies.22,35
There was no significant difference in preserving visual 
function or vision-related quality of life between the two 
groups. Gazzard and colleagues13 compared conservative 
treatment with SLT for patients with newly diagnosed 
glaucoma, in which general quality of life was the 
primary outcome. The trial did not find a difference in 
quality of life between the two intervention groups.
Besides the superior efficacy, comparable safety, and 
acceptance of SLT, cost is also an important factor. Out-
of-pocket payment is still common in many countries 
and, even if national health insurance options are 
available, uptake might still be low.15 If an eye care unit 
uses SLT to treat at least 500 eyes with glaucoma per year, 
SLT laser therapy can be offered for around US$12·50, 
including estimates for salaries, cost of repair, and 









Total 10 (10%) 8 (8%) 18 (9%)
Ocular
Conjunctiva injected 2 (2%) 1 (1%) 3 (1%)




Cardiovascular event 1 (1%) 1 (1%) 2 (1%)
Diabetes 3 (3%) 1 (1%) 4 (2%)
Orthopaedic condition 2 (2%) 2 (2%) 4 (2%)
Prostate surgery 1 (1%) 0 1 (<1%)
Death 1 (1%) 3 (3%) 4 (2%)
Data are n (%). *Requiring hospital admission.









Adherence every day 53 (56%) 62 (69%) 35 (69%) 27 (75%)
Non-adherence for 1–2 days 23 (24%) 13 (14%) 10 (20%) 7 (19%)
Non-adherence for >2 days 19 (20%) 14 (16%) 2 (4%) 2 (6%)
Adherence to treatment was assessed at each follow-up by asking participants how frequently they took their eye drops 
during the previous 2 weeks. Assessment continued for participants until the respective study exit (eg, failure, loss to 
follow-up, or success at 12 months). *One reply missing. †Three replies missing.
Table 4: Self-reported adherence to eye drops for participants in the timolol group
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can be high in regions where specialised service 
personnel sometimes need to be flown in or the 
equipment needs to be shipped abroad for maintenance 
or repair.36 The salaries of ophthal mologists and other 
eye care professionals are a crucial component. Both 
treatments can be offered as an affordable intervention 
for glaucoma using the annual gross domestic product 
per capita as a surrogate for income and an affordability 
threshold of 2·5%.26
Our trial has several limitations. To establish the IOP-
lowering effect or the efficacy as accurately as possible, 
adherence to regular follow-up visits and eye drops was 
promoted through intensive counselling, phone call 
reminders, and subsidies for travel and treatment 
expenses. Although these efforts resulted in high follow-
up rates, they are also a limitation of the study given that 
the results probably underestimate the difference 
between laser and eye drops, favouring timolol through 
the provision of free treatment, more intensive 
counselling, and transport support. Eye drops need to be 
applied daily and new bottles need to be purchased every 
few weeks for consistent IOP control. By contrast, SLT 
treatment requires only occasional IOP measurements 
and retreatments, if the IOP increases. SLT was 
consistently performed by one experienced eye surgeon, 
which assisted in determining the best possible efficacy 
of the procedure; however, such efficacy might not always 
be achieved, especially while eye care professionals are in 
their learning curve. A further limitation is the follow-up 
of 1 year. Although 1 year is a sufficient period to estimate 
the IOP-lowering potential of the interventions in our 
cohort, changes in visual outcomes, vision-related quality 
of life, long-term effects on IOP lowering, and the 
progression of glaucoma might only become apparent 
over a longer period of time. Longer follow-up would also 
allow target IOPs to be evaluated on and adjusted for 
particular eyes if necessary. Treatment affordability and 
cost were used to compare the two treatment alternatives, 
which is of particular relevance in regions with a 
high proportion of out-of-pocket payments. However, 
more comprehensive economic evaluations, such as an 
extended cost-effectiveness analysis that adds non-
health benefits, including the financial risk protection 
and distributional consequences (eg, equity), are 
also particularly relevant in these regions and should 
be considered in future studies. Furthermore, it could 
be argued that alternative topical treatments, such as 
prostaglandin analogues, might have been more effective 
than timolol. However, our choice was deliberate because 
timolol is the current standard of care in the region, and 
such alternatives are either unavailable or prohibitively 
expensive.8
The target threshold of 18 mm Hg for advanced 
glaucoma was informed by the associative analysis of 
the AGIS trial, which found this threshold to be 
protective against further progression during a follow-
up period of 6 years. It is noteworthy that AGIS also 
included patients with low baseline IOP, whereas our 
study enrolled patients with high-pressure glaucoma 
only (IOP >21 mm Hg).
The results from this trial suggest that SLT can be used 
instead of timolol eye drops, the current first-line 
treatment in sub-Saharan Africa. If glaucoma progresses 
further, SLT can be repeated or combined with eye drops 
before resorting to trabeculectomy, which remains an 
important treatment option for patients with glaucoma. 
Additionally, if surgeons are not confident in performing 
trabeculectomy (eg, in patients with end-stage glaucoma 
or when patients refuse surgery), SLT could have an 
important role. The initial investment cost can be offset, 
in this context, by completing around 500 procedures 
per year over 10 years. The laser treatment option could 
be embedded in a comprehensive glaucoma management 
network strategy based around large eye units equipped 
with an SLT laser. This strategy would need to be closely 
associated with improving community awareness, 
enabling early detection of glaucoma in primary care 
settings, and strengthening the referral pathways to 
these large eye units. Such an approach could increase 
the demand for affordable and convenient glaucoma 
treatment options, such as SLT.15
In summary, the prevalence of glaucoma is set to 
increase due to ageing and population growth, mainly 
in resource-limited settings.5,37,38 The Lancet Global 
Health Commission on global eye health suggested 
that research action is urgently needed to develop 
contextually relevant management strategies for 
glaucoma.38 The findings from this trial clearly indicate 
that SLT is superior to timolol eye drops in controlling 
IOP in patients with open-angle glaucoma in Tanzania. 
Both interventions showed similar safety profiles, 
acceptance by patients, vision-related quality of life, and 
preservation of visual acuity. Depending on the number 
of procedures and the funding model, SLT treatment 
can be offered at a similar cost to a 1-year supply of 
timolol eye drops. Ultimately, this trial, completed in 
Africa, provides strong evidence that SLT can contribute 
to an affordable management strategy for preventing 
blindness from glaucoma. 
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